Cargando…

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial

RATIONALE: Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogelmeier, Claus F., Kerwin, Edward M., Bjermer, Leif H., Tombs, Lee, Jones, Paul W., Boucot, Isabelle H., Naya, Ian P., Lipson, David A., Compton, Chris, Barnes, Neil, Maltais, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659027/ https://www.ncbi.nlm.nih.gov/pubmed/33167780 http://dx.doi.org/10.1177/1753466620968500

Ejemplares similares

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial
por: Bjermer, Leif, et al.
Publicado: (2021)

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial
por: Maltais, F., et al.
Publicado: (2020)

Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial
por: Bjermer, Leif H., et al.
Publicado: (2021)

Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial
por: Kerwin, Edward M, et al.
Publicado: (2020)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
por: Vogelmeier, Claus F., et al.
Publicado: (2021)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
por: Naya, Ian, et al.
Publicado: (2019)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials
por: Ray, Riju, et al.
Publicado: (2018)

Bronchodilator response of advanced lung function parameters depending on COPD severity
por: Jarenbäck, Linnea, et al.
Publicado: (2016)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Alcázar Navarrete, Bernardino, et al.
Publicado: (2018)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
por: Vogelmeier, Claus F., et al.
Publicado: (2022)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Effects of baseline symptom burden on treatment response in COPD
por: Martinez, Fernando J, et al.
Publicado: (2019)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Long-term outcomes following first short-term clinically important deterioration in COPD
por: Naya, Ian P., et al.
Publicado: (2018)

Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD
por: Borel, Benoit, et al.
Publicado: (2016)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline
por: Jeong, Ho Jung, et al.
Publicado: (2016)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Stereomicroscopic Evaluation of Marginal Fit of E.Max Press and E.Max Computer-Aided Design and Computer-Assisted Manufacturing Lithium Disilicate Ceramic Crowns: An In vitro Study
por: Elrashid, Afra Hassan, et al.
Publicado: (2019)

COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
por: Kardos, Peter, et al.
Publicado: (2020)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

A new protocol for exercise testing in COPD; improved prediction algorithm for W(MAX) and validation of the endurance test in a placebo-controlled double bronchodilator study
por: Tufvesson, Ellen, et al.
Publicado: (2021)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3mdal9va40h2m7vecqevugke73